Seres Therapeutics, Inc.
MCRB
$6.33
$0.050.80%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 358.00K | 438.00K | 351.00K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 358.00K | 438.00K | 351.00K | -- | -- |
| Cost of Revenue | 13.20M | 12.28M | 13.35M | 14.63M | 15.35M |
| Gross Profit | -12.84M | -11.84M | -13.00M | -14.63M | -15.35M |
| SG&A Expenses | 8.07M | 7.54M | 9.48M | 10.25M | 11.89M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.27M | 19.82M | 22.83M | 24.88M | 27.24M |
| Operating Income | -20.91M | -19.38M | -22.48M | -24.88M | -27.24M |
| Income Before Tax | -19.91M | -15.34M | 8.20M | -19.86M | 32.68M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.91M | -15.34M | 8.20M | -19.86M | 32.68M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.91M | -15.34M | 8.20M | -19.86M | 32.68M |
| EBIT | -20.91M | -19.38M | -22.48M | -24.88M | -27.24M |
| EBITDA | -20.13M | -18.42M | -21.43M | -23.82M | -26.16M |
| EPS Basic | -2.08 | -1.66 | 0.94 | -2.27 | 3.76 |
| Normalized Basic EPS | -1.30 | -1.12 | -1.36 | -1.43 | -1.40 |
| EPS Diluted | -2.08 | -1.66 | 0.94 | -2.27 | 3.75 |
| Normalized Diluted EPS | -1.30 | -1.12 | -1.36 | -1.43 | -1.40 |
| Average Basic Shares Outstanding | 9.58M | 9.23M | 8.76M | 8.74M | 8.70M |
| Average Diluted Shares Outstanding | 9.58M | 9.23M | 8.77M | 8.74M | 8.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |